Link to this page

Your search term(s) "Diagnostic Tests" returned 58 results.

Page 1 2 3 4 5 6    Display All

Hodgkin’s Lymphoma. IN: Sekeres, M.; Kalaycio, M.; Bolwell, B., eds. Clinical Malignant Hematology. Columbus, OH: McGraw Hill. 2007. pp 733-814.

This section about Hodgkin’s lymphoma (HL) is from a comprehensive reference book that covers the full spectrum of cancers in the blood, bone marrow, and lymphatic system, including leukemia, lymphoma, and myeloma. This section offers nine chapters: epidemiology and risk factors; prognostic factors in HL; the classification, pathology, and molecular genetics of HL; clinical features and making the diagnosis; the suggested treatment approach to classical HL; the treatment approach to nodular lymphocyte-predominant HL; the use of autologous stem cell transplantation for HL; follow-up care for patients with HL; and treatment of relapse or refractory HL and new frontiers in HL therapy. The authors note that HL can now be cured in more than 80 percent of patients, irrespective of the anatomical stage of disease and of its histologic type. The chapters are illustrated with black-and-white clinical pictures and photomicrographs. Each chapter concludes with an extensive list of references.

Full Record   Printer Friendly Version

Acute Lymphoblastic Leukemia. IN: Sekeres, M.; Kalaycio, M.; Bolwell, B., eds. Clinical Malignant Hematology. Columbus, OH: McGraw Hill. 2007. pp 103-158.

This section on acute lymphoblastic leukemia (ALL) is from a comprehensive reference book that covers the full spectrum of cancers in the blood, bone marrow, and lymphatic system, including leukemia, lymphoma, and myeloma. The authors note that ALL is a complex and potentially curable hematopoietic cancer that has provided numerous advances in the treatment of malignant diseases for both children and adults. This section offers six chapters: epidemiology, risk factors, and classification; molecular biology, pathology, and cytogenetics of ALL; clinical features and making the diagnosis; treatment approach to adult acute lymphoblastic leukemia; definition of remission, prognosis, and follow-up in patients with ALL; and treatment of relapsed or refractory ALL and new frontiers in therapy for AML. The chapters include full coverage of all treatment options such as chemotherapy, monoclonal antibodies, and hematopoietic stem cell transplantation. The chapters are illustrated with black-and-white clinical pictures and photomicrographs. Each chapter concludes with an extensive list of references.

Full Record   Printer Friendly Version

Acute Myeloid Leukemia. IN: Sekeres, M.; Kalaycio, M.; Bolwell, B., eds. Clinical Malignant Hematology. Columbus, OH: McGraw Hill. 2007. pp 1-102.

This section on acute myeloid leukemia (AML) is from a comprehensive reference book that covers the full spectrum of cancers in the blood, bone marrow, and lymphatic system, including leukemia, lymphoma, and myeloma. This section offers nine chapters: epidemiology, risk factors, and classification; molecular biology, pathology, and cytogenetics of AML; clinical features and making the diagnosis; treatment for AML in patients less than 60 years of age; treatment approach to AML in older adults; treatment approach to acute promyelocytic leukemia; approaches to the treatment of secondary AML and advanced myelodysplasia; definition of remission, prognosis, and follow-up in patients with AML; and treatment of relapsed or refractory AML and new frontiers in therapy for AML. The chapters include full coverage of all treatment options such as chemotherapy, monoclonal antibodies, and hematopoietic stem cell transplantation. The chapters are illustrated with black-and-white clinical pictures and photomicrographs. Each chapter concludes with an extensive list of references.

Full Record   Printer Friendly Version

All About Von Willebrand Disease...For People With Von Willebrand Disease And Their Families. 2nd ed. Montreal, QC: Canadian Hemophilia Society. 2007. 87 p.

This monograph from the Canadian Hemophilia Society provides comprehensive information about von Willebrand disease (VWD), a disease characterized by problems in the von Willebrand factor (VWF). The VWF is a protein in the blood that is necessary for proper blood coagulation. When there is not enough VWF in the blood, or when it does not work the way it should, the blood takes longer to clot. This booklet reviews the different types of VWD, the role of heredity, the symptoms, diagnostic tests that can confirm the condition, treatment options, and strategies for healthy living with VWD. The lifestyle factors discussed include the safety of blood products, coping with nose bleeds, conception, pregnancy and childbirth, medications to avoid, exercise, fitness and sports, child care, schooling, employment, insurance, traveling, and medical identification. The booklet concludes with the contact information for the Canadian Hemophilia Society, a list of hemophilia or bleeding disorders treatment centers in Canada, a glossary of terms, a subject index, and a bibliography. The booklet includes black-and-white illustrations. 6 references.

Full Record   Printer Friendly Version

Antiphospholipid Syndrome. IN: Hematology 2007. Washington, DC: American Society of Hematology. 2007. pp.136-142.

This chapter, from the annual Hematology 2007, describes the antiphospholipid syndrome (APS), an autoimmune thrombophilic condition that is marked by the presence of antibodies that recognize phospholipid-binding proteins. Patients with APS tend to present with vascular thrombosis and pregnancy complications, especially recurrent, spontaneous miscarriages. The author focuses on updated diagnostic and therapeutic approaches to this disorder. The author recommends that testing for antiphospholipid (aPL) antibodies should usually be restricted to patients who have had thrombosis, embolism, or pregnancy complications that may be attributable to APS, and to patients with systemic lupus erythematosus (SLE) even if they have not had these manifestations. An initial venous thromboembolism (VTE) in patients with confirmed APS should be treated with warfarin. Recurrence of VTE in the face of standard treatment should be treated with higher intensity coagulation or in selected situations with a form of low-molecular-weight heparin (LMWH). For pregnant patients with VTE, the author recommends treatment with prophylactic dose heparin plus low-dose aspirin (81 milligrams daily), with modification of administration for delivery, followed by resumption of prophylactic anticoagulation. 2 figures. 3 tables. 41 references.

Full Record   Printer Friendly Version

Carrier Testing. Montreal, Quebec: Canadian Hemophilia Society. 2007. pp 43-56.

This chapter on carrier testing is from a monograph that provides information for female carriers of hemophilia A and B, a type of genetic bleeding disorder traditionally experienced by males but passed on genetically by females. Recent understanding of this disorder shows that females can have the same problems as males with mild hemophilia, such as hemorrhaging after surgery or trauma. Women with clotting factor levels as high as 60 percent can have abnormal bleeding problems, including but not restricted to gynecological and obstetrical bleeding. This chapter explains why, when, and where to get tested for hemophilia; the tests that determine factor levels and carrier status; and some of the psychosocial issues related to testing and diagnosis. The authors address the controversy about whether to test in childhood, specifically before puberty, or to wait until the woman is an adult and can make the decision herself. The authors contend that earlier testing is better, both for medical reasons as well as to give the girl time to adjust to the diagnosis and educate herself about treatment and lifestyle options. Readers are encouraged, in all cases, to consult a hemophilia treatment team that can help them through the decision process as well as with follow-up counseling, as necessary.

Full Record   Printer Friendly Version

Chronic Lymphocytic Leukemia. IN: Sekeres, M.; Kalaycio, M.; Bolwell, B., eds. Clinical Malignant Hematology. Columbus, OH: McGraw Hill. 2007. pp 213-264.

This section on chronic lymphocytic leukemia (CLL) is from a comprehensive reference book that covers the full spectrum of cancers in the blood, bone marrow, and lymphatic system, including leukemia, lymphoma, and myeloma. The authors note that CLL is characterized by the accumulation of monoclonal malignant B cells in the blood, lymph nodes, liver, spleen, and bone marrow. This section offers six chapters: epidemiology, risk factors, and classification; molecular biology, pathology, and cytogenetics of CLL; clinical features and making the diagnosis; the indications for treatment and the recommended treatment approach for CLL; response criteria, prognosis, and follow-up in patients with CLL; and aggressive transformation and paraneoplastic complications of CLL. The chapters include full coverage of all treatment options such as chemotherapy, monoclonal antibodies, and hematopoietic stem cell transplantation. The chapters are illustrated with black-and-white clinical pictures and photomicrographs. Each chapter concludes with an extensive list of references.

Full Record   Printer Friendly Version

Chronic Myelogenous Leukemia. IN: Sekeres, M.; Kalaycio, M.; Bolwell, B., eds. Clinical Malignant Hematology. Columbus, OH: McGraw Hill. 2007. pp 159-212.

This section on chronic myelogenous leukemia (CML) is from a comprehensive reference book that covers the full spectrum of cancers in the blood, bone marrow, and lymphatic system, including leukemia, lymphoma, and myeloma. The authors note that CML is a form of chronic myeloproliferative disease (CMPD) with a well-defined genetic defect, characterized by proliferation in the bone marrow of one or more of the myeloid cell lineages that gradually displaces normal hematopoiesis. This section offers six chapters: epidemiology, risk factors, and classification; molecular biology, pathology, and cytogenetics of CML; the treatment approach to chronic-phase CML; the treatment approach to accelerated-phase or blast-crisis CML; definition of remission, prognosis, and follow-up in patients with CML; and new frontiers in the treatment of relapsed or refractory CML. The chapters include full coverage of all treatment options such as chemotherapy, monoclonal antibodies, and hematopoietic stem cell transplantation. The chapters are illustrated with black-and-white clinical pictures and photomicrographs. Each chapter concludes with an extensive list of references.

Full Record   Printer Friendly Version

Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice. IN: Hematology 2007. Washington, DC: American Society of Hematology. 2007. pp 376-383.

This article reviews the multifaceted role of molecular monitoring for patients with chronic myeloid leukemia (CML). Measurements taken during the first 18 months of first-line imatinib therapy are prognostic and provide warning signals of suboptimal response. Serial measurements for patients with a complete cytogenetic response determine ongoing treatment efficacy or can signal pending relapse. The pattern of molecular and cytogenetic response is generally comparable, but only cytogenetic analysis can monitor for the acquisition of clonal abnormalities. For patients treated with imatinib, a rising level of BCR-ABL is a trigger for kinase domain mutation analysis. The author stresses that characterization of BCR-ABL inhibitor-resistant mutations is important to direct treatments because each resistant mutation functions as a distinct protein with unique biological properties that may confer a gain or loss of function. The author concludes that the benefit to patients of regular molecular analysis is a reassurance of ongoing response using the most sensitive of techniques or a potential improvement in outcome for those where relapse is indicated early. However, despite the obvious benefits of molecular analysis, the measurement techniques may not be quite ready for acceptance into the routine clinical monitoring practices of all clinicians. The author provides specific examples from her clinical practice of the use of peripheral blood (PD), RQ-PCR analysis, and direct sequencing of the BCR-ABL kinase domain. The author concludes by calling for standardizing and simplifying the methods used for incorporation into routine laboratory testing procedures.

Full Record   Printer Friendly Version

Chronic Myeloproliferative Diseases. IN: Sekeres, M.; Kalaycio, M.; Bolwell, B., eds. Clinical Malignant Hematology. Columbus, OH: McGraw Hill. 2007. pp 445-502.

This section about chronic myeloproliferative disorders (CMPDs) is from a comprehensive reference book that covers the full spectrum of cancers in the blood, bone marrow, and lymphatic system, including leukemia, lymphoma, and myeloma. CMPDs are characterized by the chronic proliferation of one or more of the three hematopoietic cell lines or by marrow stromal cells, in various proportions. The CMPDs include polycythemia vera, idiopathic myelofibrosis, chronic myelogenous leukemia (CML), and essential thrombocytosis (ET). This section offers six chapters: epidemiology, risk factors, and classification; molecular biology, pathology, and cytogenetics; clinical features and making the diagnosis; the recommended treatment approach to polycythemia vera and essential thrombocythemia; the recommended approach to chronic idiopathic myelofibrosis, with extramedullary hematopoiesis; and the management of chronic myelomonocytic leukemia and other rare myeloproliferative disorders. The chapters are illustrated with black-and-white clinical pictures and photomicrographs. Each chapter concludes with an extensive list of references.

Full Record   Printer Friendly Version

Page 1 2 3 4 5 6    Display All

Start a new search.